Cagrilintide Dosage With Tirzepatide: Full Reconstitution & Dosing Chart | FormBlends

Trust Signals

Direct Answer: Cagrilintide Dosage With Tirzepatide

No published human RCT has established a validated cagrilintide dose specifically paired with tirzepatide. Research protocols adapted from the CagriSema program commonly start cagrilintide at 0.3 to 0.6 mg weekly alongside a low tirzepatide dose (2.5 mg), escalating each agent separately every four weeks. Both drugs carry overlapping GI adverse event profiles; this amplifies nausea and vomiting risk during co-escalation.

Evidence Ledger

Each major claim on this page is graded below. Confidence ratings follow standard evidence hierarchy: human RCT evidence rates higher than animal or mechanistic data.

Mechanism: How Tirzepatide and Cagrilintide Work Together (With Numbers)

Tirzepatide is a 39-amino-acid dual GIP/GLP-1 receptor agonist with a molecular weight of approximately 4,813 Da. It was designed as a GIP-based scaffold with C18 fatty diacid modification at lysine-26, which confers albumin binding and a half-life of approximately 5 days in humans, enabling once-weekly subcutaneous dosing.

At the receptor level, tirzepatide binds the GIP receptor with roughly equivalent potency to native GIP and the GLP-1 receptor with somewhat lower potency than native GLP-1, but both are activated at therapeutic plasma concentrations. In the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), the 15 mg dose arm achieved a mean weight reduction of 20.9% from baseline at 72 weeks in a population with obesity without diabetes.

Cagrilintide is a long-acting amylin analogue (half-life approximately 7 days in humans, per Novo Nordisk phase 1 data). Amylin acts primarily on area postrema and nucleus tractus solitarius receptors to slow gastric emptying and reduce meal-time caloric intake. Its mechanism is distinct from and complementary to GLP-1R agonism. In the COMBINE 1 phase 2 trial published in The Lancet (2023), cagrilintide 2.4 mg plus semaglutide 2.4 mg weekly produced greater mean weight loss than either monotherapy in adults with obesity over 32 weeks.

What this mechanism does NOT prove: Greater mechanistic complementarity does not guarantee additive or synergistic benefit when cagrilintide is combined with tirzepatide specifically, because tirzepatide's GIP component already modifies gastric function and pancreatic signaling through pathways that partially overlap with amylin signaling. Whether stacking cagrilintide on top of a dual GIP/GLP-1 agonist adds more benefit than either alone has not been tested in a published human trial.

Tirzepatide Reconstitution Chart: 5 mg to 30 mg Vials

Unit column assumes a U-100 insulin syringe (100 units = 1 mL). If you use a U-40 syringe, the unit-to-volume ratio is different. Verify syringe type before drawing.

How Many Units Is 5 mg of Tirzepatide?

This question has no single answer. The unit count depends entirely on your reconstitution volume. Here is the math:

Formula: Units to draw = (Desired dose in mg / Concentration in mg per mL) x 100

Example: You want 5 mg, your vial is 10 mg reconstituted in 2 mL (5 mg/mL). Draw volume = 5 / 5 = 1.0 mL = 100 units on a U-100 syringe.

How Much Bacteriostatic Water to Mix With 10 mg and 30 mg Tirzepatide

For a 10 mg vial: Adding 2 mL of bacteriostatic water gives a 5 mg/mL concentration. This is a practical mid-range: not so concentrated that small drawing errors cause large dose errors, and not so dilute that you are injecting large injection volumes for low doses. Adding 1 mL gives 10 mg/mL, which is more concentrated and requires smaller, more precise draws.

For a 30 mg vial: Adding 3 mL yields 10 mg/mL. Adding 6 mL yields 5 mg/mL. The 3 mL option keeps total vial volume smaller and is more common in research protocols that administer 5 to 15 mg weekly doses. The 6 mL option trades vial space for slightly more forgiving draw precision.

Why not sterile water? See the chemistry section below. The short answer is that benzyl alcohol in bacteriostatic water acts as an antimicrobial preservative, allowing multi-dose use over weeks. Sterile water without preservative is a single-use diluent only.

Cagrilintide Escalation Alongside Tirzepatide

In the COMBINE 1 trial (Enebo et al., The Lancet, 2021 phase 2 data; updated full results 2023), cagrilintide was escalated from 0.3 mg weekly up to 2.4 mg weekly over approximately 16 weeks. The semaglutide arm was simultaneously titrated. This co-escalation approach is the only published human protocol involving cagrilintide dose titration with a GLP-1 axis drug.

Research protocols that adapt this approach for tirzepatide combinations commonly use the following structure, though this is not validated in a published human RCT:

Caveat: This table represents an adaptation, not a validated protocol. Overlapping GI adverse events (nausea, vomiting) from both agents during co-escalation make slower titration schedules more practical. Any use of cagrilintide outside an approved regimen should occur under direct clinical supervision.

Tirzepatide 30 mg: What the Evidence Actually Says

The SURMOUNT-1 trial maximum dose was 15 mg weekly. SURPASS-2 and other pivotal trials also used 15 mg as the ceiling. The FDA-approved Zepbound and Mounjaro labels cap maintenance dosing at 15 mg weekly.

A 30 mg weekly dose is exactly double the highest studied and approved maintenance dose. There are no published large-sample human RCTs evaluating 30 mg weekly tirzepatide. Dose-dependent GI adverse events (nausea, vomiting, diarrhea, constipation) were already the primary tolerability limitation in the 5 to 15 mg range in SURMOUNT-1. Extrapolating that dose-response curve upward suggests, but does not prove, meaningfully worse tolerability at 30 mg without a clear evidence base for proportionally greater efficacy.

What Most Dosage Pages Get Wrong

1. Stating a universal bac water volume without explaining concentration consequences. Telling someone to "add 1 mL" without specifying that every subsequent draw volume is now different is how dosing errors happen. The bac water volume is a math choice, not a rule.

2. Treating cagrilintide and tirzepatide as an established combination. The clinical evidence is for CagriSema (cagrilintide plus semaglutide). Applying that protocol to tirzepatide is an untested extrapolation. The distinction matters because tirzepatide's GIP component adds pharmacology that semaglutide lacks, and the interaction with amylin signaling from cagrilintide in that context is genuinely unknown.

3. Ignoring vial pressure when adding bac water. Lyophilized peptide vials are sealed under slight negative pressure. Adding too much liquid volume to a small vial can create pressure issues during needle insertion and withdrawal. When reconstituting a 30 mg vial with 6 mL, the total volume in a standard 10 mL vial is manageable, but adding this volume to a smaller vial format risks spray or vial cracking. Confirm your vial capacity before selecting a reconstitution volume.

4. Omitting degradation signs. A degraded tirzepatide solution may appear as: increased turbidity or cloudiness (precipitation), unusual color shift from clear toward yellow, or visible particulates. If any of these appear, the vial should not be used. Degradation is not always visible; it can occur at the molecular level while the solution looks normal, which is why temperature control and use-within-28-days guidance exist.

Why Bacteriostatic Water and Not Sterile Water: The Chemistry Behind the Rule

Bacteriostatic water for injection (BWI) contains 0.9% benzyl alcohol w/v. Benzyl alcohol at this concentration is bacteriostatic (it inhibits bacterial reproduction) without being fully bactericidal. This matters for multi-dose vials because each needle insertion introduces a small contamination risk. The benzyl alcohol prevents microbial growth over the typical use period, which is why multi-dose vials reconstituted with BWI are generally considered usable for up to 28 days refrigerated.

Sterile water for injection (SWFI) contains no preservative. A vial reconstituted with SWFI should be used immediately or discarded, because any contamination introduced during reconstitution or drawing has no bacteriostatic check. This is not a formulation preference; it is a contamination control issue.

The pH consideration: Tirzepatide and most GLP-1-class peptides are stable at mildly acidic to neutral pH. Bacteriostatic water has a pH typically between 4.5 and 7.0, which is compatible with peptide stability. Normal saline (0.9% NaCl) can be used but adds chloride ions and has a slightly different pH profile. Some peptides are sensitive to ionic strength changes. For tirzepatide specifically, the approved pen formulations use a proprietary buffer, and reconstituted research vials in bacteriostatic water approximate but do not replicate that formulation exactly.

Benzyl alcohol toxicity note: BWI is contraindicated in neonates and should be used with caution in patients with documented benzyl alcohol sensitivity. For most adults, the 0.9% concentration in BWI is well below systemic toxicity thresholds even with weekly injections.

Honest Head-to-Head: Tirzepatide vs. Semaglutide vs. CagriSema

Label and COA Literacy: How to Judge What You Have

For research-grade lyophilized tirzepatide or cagrilintide, the minimum acceptable certificate of analysis (COA) should include all of the following. If any are absent, ask the supplier for them before use.

Reading the purity number: A supplier listing "99% purity" without stating the analytical method is providing an unverifiable claim. Ask specifically for the H